The human ErbB3 receptor confers resistance to the pharmacological inhibition of EGFR and HER2 receptor tyrosine kinases in most cancers, which makes it an essential therapeutic goal. A number of
The human ErbB3 receptor confers resistance to the pharmacological inhibition of EGFR and HER2 receptor tyrosine kinases in most cancers, which makes it an essential therapeutic goal. A number of